← 產業報告目錄

Endoscopic Submucosal Dissection/ESD Market by Product (Gastroscopes & Endoscopes, Injection Agent, Tissue Retractor), Indication (Stomach Cancer, Colon Cancer), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-08-27頁數 235報告編號 MD8538

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The endoscopic submucosal dissection market is projected to reach USD 0.75 billion by 2030 from USD 0.50 billion in 2025, at a CAGR of 8.4% during the forecast period. Technological advancements in endoscopic submucosal dissection (ESD) tools are significantly enhancing the procedure's clinical utility and safety, which, in turn, is driving market growth. Innovations such as hybrid knives that combine both injection and cutting capabilities have streamlined the dissection process and reduced procedural time. Additionally, traction-assisted systems have improved visualization and access to submucosal layers, making complex dissections more manageable. High-definition and narrow-band imaging (NBI) endoscopes have further enhanced the detection of lesions and assessment of margins, resulting in increased procedural accuracy and better patient outcomes. Companies like Olympus and Fujifilm are heavily investing in platform-specific innovations, integrating energy delivery systems, ergonomic endoscope designs, and AI-based visualization aids. These developments are reducing the technical barriers traditionally associated with ESD, enabling broader adoption in non-academic and community healthcare settings. As these tools become more intuitive and standardized, they are facilitating the learning process for new practitioners, ultimately making ESD more accessible and preferred for the management of early-stage gastrointestinal tumors worldwide. By product, the gastroscopes & endoscopes segment accounted for the largest share of the market in 2024. The market for endoscopic submucosal dissection (ESD) is categorized by product type into gastroscopes & endoscopes, knives, injection agents, tissue retractors, grasping clips, and other products. In 2024, the segment for gastroscopes & endoscopes held the largest share of the global ESD market. Recent advancements in high-definition (HD) and 4K ultra-high-definition (UHD) imaging technologies have transformed ESD procedures by providing superior optical clarity and detailed visualization. Features such as narrow-band imaging (NBI), magnification endoscopy, and 4K scopes significantly enhance the detection of lesions, delineation of margins, and overall procedural accuracy. These imaging enhancements reduce the likelihood of diagnostic errors and allow for more precise dissection, ultimately leading to improved patient outcomes. Consequently, gastroscopes & endoscopes play a vital role in these advancements, which is why they dominate the market share in the ESD sector, driven by their essential contribution to the success of these procedures. Based on indications, the stomach cancer segment dominated the ESD market in 2024. Based on indications, the ESD market is divided into three categories: stomach cancer, colon cancer, and esophageal cancer. In 2024, stomach cancer accounted for the largest share of the ESD market. Strong clinical evidence supports ESD as the gold standard for treating mucosal and superficial submucosal gastric tumors. Long-term studies have shown that ESD achieves high rates of en bloc resection, minimal local recurrence, and excellent organ preservation, especially when compared to traditional surgery. These outcomes are particularly significant for early-stage stomach cancers, where a curative approach without major surgery is preferred. Consequently, the stomach cancer segment leads the ESD market, driven by strong clinical validation and high procedural volumes in the management of gastric lesions. Based on region, the Asia Pacific held the largest market share in 2024. The Asia Pacific region is projected to hold the largest share of the ESD market during the forecast period. Government-funded screening programs in Japan and South Korea are actively promoting the early detection of gastric and colorectal lesions through endoscopy, which has significantly increased ESD volumes. This region has also been at the forefront of adopting advanced medical technology to enhance patient care and safety. A breakdown of the primary participants (supply side) for the endoscopic submucosal dissection market referred to in this report is provided below: • By Company Type: Tier 1 (34%), Tier 2 (38%), and Tier 3 (28%) • By Designation: C-level Executives (26%), Directors (35%), and Others (39%) • By Region: North America (17%), Europe (39%), Asia Pacific (28%), Latin America (8%), Middle East & Africa (3%), and GCC Countries (5%) Prominent players in the endoscopic submucosal dissection market are Olympus Corporation (Japan), FUJIFILM Holdings Corporation (Japan), Medtronic (Ireland), Boston Scientific Corporation (US), and Sumitomo Bakelite Co., Ltd. (Japan). Research Coverage The report assesses the endoscopic submucosal dissection market, estimating its size and future growth potential across various segments, including products, indications, end users, and regions. Additionally, the report features a competitive analysis of key players in the market, along with company profiles, product offerings, recent developments, and essential market strategies. Reasons to Buy the Report The report will provide valuable data on revenue estimates for the overall endoscopic submucosal dissection market and its subsegments, benefiting both market leaders and new entrants. It will help stakeholders understand the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, the report will give stakeholders insights into market trends, including key drivers, challenges, restraints, and opportunities. This report provides insights into the following points:  Analysis of key drivers (increasing use of endoscopy in detection and treatment procedures and rising prevalence of cancer), restraints (dearth of skilled professionals and high overhead cost of ESD procedures with limited reimbursements), opportunities (growing demand for minimally invasive procedures, growing investments in R&D of endoscopy technology, and expected increase in adoption of and preference for ESD procedures in developing countries), and challenges (higher rate of complications and risk of post-operative infections). • Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global ESD market. • Market Development: Thorough knowledge and analysis of the profitable rising markets by product, indication, end user, and region. • Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global ESD market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global ESD market.
目錄 Table of Contents
1 INTRODUCTION 23 1.1 STUDY OBJECTIVES 23 1.2 MARKET DEFINITION 23 1.3 STUDY SCOPE 24 1.3.1 SEGMENTS COVERED 24 1.3.2 INCLUSIONS AND EXCLUSIONS 25 1.4 YEARS CONSIDERED 25 1.5 CURRENCY USED 26 1.6 STAKEHOLDERS 26 1.7 LIMITATIONS 27 1.8 SUMMARY OF CHANGES 27 2 RESEARCH METHODOLOGY 28 2.1 RESEARCH DATA 28 2.1.1 SECONDARY DATA 28 2.1.1.1 Key data from secondary sources 30 2.1.2 PRIMARY DATA 30 2.1.2.1 Key data from primary sources 31 2.1.2.2 Key industry insights 32 2.2 MARKET SIZE ESTIMATION 34 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 39 2.4 MARKET SHARE ESTIMATION 41 2.5 STUDY ASSUMPTIONS 41 2.6 METHODOLOGY-RELATED LIMITATIONS 41 2.7 RISK ASSESSMENT 42 3 EXECUTIVE SUMMARY 43 4 PREMIUM INSIGHTS 46 4.1 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET OVERVIEW 46 4.2 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT AND COUNTRY 47 4.3 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: GEOGRAPHIC MIX 48 4.4 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION 48 4.5 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DEVELOPED VS. DEVELOPING MARKETS 49   5 MARKET OVERVIEW 50 5.1 INTRODUCTION 50 5.2 MARKET DYNAMICS 50 5.2.1 DRIVERS 51 5.2.1.1 Increasing use of endoscopy in detection and treatment procedures 51 5.2.1.2 Rising prevalence of cancer 51 5.2.1.3 Growing geriatric population 52 5.2.2 RESTRAINTS 53 5.2.2.1 Dearth of skilled professionals 53 5.2.2.2 High overhead cost of ESD procedures with limited reimbursements 53 5.2.3 OPPORTUNITIES 53 5.2.3.1 Growing demand for minimally invasive procedures 53 5.2.3.2 Expected increase in adoption of and preference for ESD procedures in developing countries 54 5.2.4 CHALLENGES 54 5.2.4.1 Higher rate of complications 54 5.2.4.2 Risk of post-operative infection 54 5.3 INDUSTRY TRENDS 55 5.3.1 ADVANCES IN TRACTION METHODS FOR ENDOSCOPIC SUBMUCOSAL DISSECTION 55 5.3.2 ROBOT-ASSISTED ENDOSCOPIC SUBMUCOSAL DISSECTION 56 5.4 REGULATORY ANALYSIS 57 5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57 5.4.2 REGULATORY LANDSCAPE 59 5.4.2.1 North America 59 5.4.2.1.1 US 59 5.4.2.1.2 Canada 59 5.4.2.2 Europe 60 5.4.2.2.1 Germany 60 5.4.2.2.2 France 61 5.4.2.2.3 UK 61 5.4.2.2.4 Italy 61 5.5 MARKET ECOSYSTEM 61 5.6 VALUE CHAIN ANALYSIS 63 5.7 PORTER’S FIVE FORCES ANALYSIS 64 5.7.1 THREAT OF NEW ENTRANTS 65 5.7.1.1 High capital requirement 65 5.7.1.2 High preference for products from well-established brands 66 5.7.2 THREAT OF SUBSTITUTES 66 5.7.2.1 Presence of substitute therapies for endoscopic submucosal dissection 66   5.7.3 BARGAINING POWER OF SUPPLIERS 66 5.7.3.1 Presence of several raw material suppliers 66 5.7.3.2 Supplier switching cost 66 5.7.4 BARGAINING POWER OF BUYERS 66 5.7.4.1 Limited number of companies offering premium products at global level 66 5.7.5 INTENSITY OF COMPETITIVE RIVALRY 66 5.7.5.1 Increasing demand for high-quality and innovative products 67 5.7.5.2 Lucrative growth potential in emerging markets 67 5.8 PRICING ANALYSIS 67 5.8.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2024 67 5.8.2 AVERAGE SELLING PRICE TREND OF KNIVES, BY REGION, 2022–2024 (USD) 68 5.9 PATENT ANALYSIS 69 5.10 SUPPLY CHAIN ANALYSIS 72 5.11 KEY CONFERENCES AND EVENTS DURING 2025–2025 74 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 75 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 75 5.12.2 BUYING CRITERIA 75 5.13 TRENDS/DISRUPTIONS AFFECTING CUSTOMER BUSINESS 76 5.13.1 TRENDS/DISRUPTION IMPACTING CUSTOMER’S BUSINESS 76 5.14 TRADE ANALYSIS 77 5.14.1 IMPORT DATA 77 5.14.2 EXPORT DATA 78 5.15 TECHNOLOGY ANALYSIS 80 5.15.1 KEY TECHNOLOGIES 80 5.15.1.1 Endoscopic electrosurgical knives 80 5.15.1.2 High-definition endoscopes 81 5.15.2 COMPLEMENTARY TECHNOLOGIES 81 5.15.2.1 Narrow band imaging/i-scan/FICE 81 5.15.2.2 Optical coherence tomography (OCT) 82 5.15.3 ADJACENT TECHNOLOGIES 82 5.15.3.1 Endoscopic mucosal resection 82 5.15.3.2 Full-thickness resection devices 83 5.16 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: ADJACENT MARKET 83 5.17 CASE STUDY ANALYSIS 83 5.17.1 ROBOTIC-ASSISTED ESD FOR ESOPHAGEAL TUMORS 83 5.17.2 COST-EFFECTIVE ESD DEVICES FOR STOMACH CANCER 84 5.17.3 PRECISION ESD FOR COLORECTAL CANCER LESIONS 84 5.18 IMPACT OF AI/GEN AI ON ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET 85 5.18.1 MARKET POTENTIAL OF AI IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET 85 5.18.2 AI USE CASES 86 5.18.3 KEY COMPANIES IMPLEMENTING AI 86 5.18.4 FUTURE OF GENERATIVE AI IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET 87 5.19 IMPACT OF 2025 US TARIFF ON ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET 87 5.19.1 KEY TARIFF RATES 88 5.19.2 PRICE IMPACT ANALYSIS 88 5.19.3 IMPACT ON END-USE INDUSTRIES 89 5.20 INVESTMENT & FUNDING SCENARIO 89 6 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT 92 6.1 INTRODUCTION 93 6.2 GASTROSCOPES & COLONOSCOPES 93 6.2.1 RISE IN COLON CANCER INCIDENCE TO DRIVE GROWTH 93 6.3 KNIVES 95 6.3.1 IMPROVED EFFICACY, SAFETY, AND COST-EFFECTIVENESS OF KNIVES TO DRIVE MARKET GROWTH 95 6.4 INJECTION AGENTS 96 6.4.1 NEED FOR LOW-COST INJECTION AGENTS TO BOOST GROWTH 96 6.5 TISSUE RETRACTORS 98 6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO AID ADOPTION 98 6.6 GRASPERS/CLIPS 100 6.6.1 PATIENT SAFETY AND HIGH PRECISION OFFERED BY GRASPERS TO DRIVE DEMAND 100 6.7 OTHER PRODUCTS 101 7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION 103 7.1 INTRODUCTION 104 7.2 STOMACH CANCER 105 7.2.1 SIGNIFICANT PROPORTION OF CANCER DEATHS TO DRIVE SEGMENT 105 7.3 COLON CANCER 107 7.3.1 INTEREST BY MEDICAL DEVICE MANUFACTURERS, CLINICAL INVESTIGATORS, AND PRACTICING CLINICIANS TO DRIVE MARKET 107 7.4 ESOPHAGEAL CANCER 109 7.4.1 GROWING PREVALENCE OF ESOPHAGEAL CANCER TO FUEL GROWTH 109 8 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER 111 8.1 INTRODUCTION 112 8.2 HOSPITALS 112 8.2.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES AND ESD PROCEDURES TO SUPPORT GROWTH 112 8.3 SPECIALTY CLINICS 114 8.3.1 TRANSITION FROM HOSPITAL-BASED PROCEDURES TO CLINIC-BASED PROCEDURES TO BOOST GROWTH 114   8.4 AMBULATORY SURGICAL CENTERS 115 8.4.1 GROWTH IN SEGMENT DRIVEN BY INCREASING NUMBER OF OUTPATIENT VISITS 115 8.5 OTHER END USERS 117 9 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION 118 9.1 INTRODUCTION 119 9.2 ASIA PACIFIC 119 9.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 119 9.2.2 JAPAN 122 9.2.2.1 Supportive medical device reimbursement policies to drive market growth 122 9.2.3 CHINA 124 9.2.3.1 Large patient population and strong need for healthcare infrastructure improvements to boost market growth 124 9.2.4 INDIA 126 9.2.4.1 Favorable government initiatives for healthcare infrastructure improvements to support market growth 126 9.2.5 SOUTH KOREA 128 9.2.5.1 Rapidly aging population and high incidence of gastrointestinal diseases to aid market growth 128 9.2.6 AUSTRALIA 130 9.2.6.1 High incidence of cancer to propel market growth 130 9.2.7 REST OF ASIA PACIFIC 132 9.3 NORTH AMERICA 133 9.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 133 9.3.2 US 136 9.3.2.1 Largest market for endoscopic submucosal dissection products 136 9.3.3 CANADA 138 9.3.3.1 Slower healthcare development over past decade to restrain growth 138 9.4 EUROPE 141 9.4.1 MACROECONOMIC OUTLOOK FOR EUROPE 141 9.4.2 GERMANY 143 9.4.2.1 Germany to account for largest share of European market 143 9.4.3 FRANCE 145 9.4.3.1 High-quality healthcare system offering coverage to all citizens to support market growth 145 9.4.4 UK 147 9.4.4.1 Investments by hospitals to purchase new and advanced endoscopic submucosal dissection equipment to propel market 147 9.4.5 ITALY 149 9.4.5.1 Receptivity of government toward high-quality and technologically advanced equipment to foster growth 149   9.4.6 SPAIN 151 9.4.6.1 Rising prevalence of cancer to drive market growth 151 9.4.7 REST OF EUROPE 153 9.5 LATIN AMERICA 154 9.5.1 INCREASING PURCHASING POWER AND HEALTHCARE AFFORDABILITY TO FAVOR MARKET GROWTH 154 9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 155 9.5.3 BRAZIL 157 9.5.3.1 Increase in private healthcare investments and rise in medical tourism to aid market growth 157 9.5.4 MEXICO 158 9.5.4.1 Increased government investment in healthcare infrastructure and technological advancements to aid market growth 158 9.5.5 REST OF LATIN AMERICA 160 9.6 MIDDLE EAST & AFRICA 162 9.6.1 ADVANCEMENTS IN HEALTHCARE INFRASTRUCTURE TO CREATE NEED FOR HOSPITAL EQUIPMENT AND MEDICAL DEVICES 162 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 162 9.7 GCC COUNTRIES 164 9.7.1 INCREASING INVESTMENT IN HEALTHCARE INFRASTRUCTURE AND GROWING MEDICAL TOURISM TO PROPEL MARKET GROWTH 164 9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 164 10 COMPETITIVE LANDSCAPE 166 10.1 OVERVIEW 166 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 166 10.3 REVENUE ANALYSIS 168 10.4 MARKET SHARE ANALYSIS 170 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 172 10.5.1 STARS 172 10.5.2 EMERGING LEADERS 172 10.5.3 PERVASIVE PLAYERS 172 10.5.4 PARTICIPANTS 172 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 174 10.5.5.1 Company footprint 174 10.5.5.2 Region footprint 175 10.5.5.3 Product footprint 176 10.5.5.4 Indication footprint 177 10.5.5.5 End user footprint 177 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 178 10.6.1 PROGRESSIVE COMPANIES 178 10.6.2 RESPONSIVE COMPANIES 178 10.6.3 DYNAMIC COMPANIES 178 10.6.4 STARTING BLOCKS 178 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 180 10.6.5.1 Detailed list of key startups/SMEs 180 10.6.5.2 Competitive benchmarking of key startups/SMEs 181 10.7 COMPANY VALUATION AND FINANCIAL METRICS 182 10.7.1 FINANCIAL METRICS 182 10.7.2 COMPANY VALUATION 183 10.8 BRAND/PRODUCT COMPARISON 183 10.9 COMPETITIVE SCENARIO 184 10.9.1 PRODUCT LAUNCHES 184 10.9.2 DEALS 185 10.9.3 EXPANSIONS 186 11 COMPANY PROFILES 187 11.1 KEY PLAYERS 187 11.1.1 OLYMPUS CORPORATION 187 11.1.1.1 Business overview 187 11.1.1.2 Products offered 188 11.1.1.3 Recent developments 189 11.1.1.3.1 Deals 189 11.1.1.3.2 Expansions 190 11.1.1.4 MnM view 190 11.1.1.4.1 Right to win 190 11.1.1.4.2 Strategic choices 190 11.1.1.4.3 Weaknesses and competitive threats 190 11.1.2 MEDTRONIC 191 11.1.2.1 Business overview 191 11.1.2.2 Products offered 192 11.1.2.3 MnM view 193 11.1.2.3.1 Right to win 193 11.1.2.3.2 Strategic choices 193 11.1.2.3.3 Weaknesses and competitive threats 193 11.1.3 FUJIFILM HOLDINGS CORPORATION 194 11.1.3.1 Business overview 194 11.1.3.2 Products offered 195 11.1.3.3 Recent developments 195 11.1.3.3.1 Product launches & approvals 195 11.1.3.3.2 Deals 196 11.1.3.4 MnM view 196 11.1.3.4.1 Right to win 196 11.1.3.4.2 Strategic choices 196 11.1.3.4.3 Weaknesses and competitive threats 196   11.1.4 BOSTON SCIENTIFIC CORPORATION 197 11.1.4.1 Business overview 197 11.1.4.2 Products offered 198 11.1.4.3 MnM view 199 11.1.4.3.1 Right to win 199 11.1.4.3.2 Strategic choices 199 11.1.4.3.3 Weaknesses and competitive threats 199 11.1.5 SUMITOMO BAKELITE CO., LTD. 200 11.1.5.1 Business overview 200 11.1.5.2 Products offered 201 11.1.5.3 MnM view 201 11.1.5.3.1 Right to win 201 11.1.5.3.2 Strategic choices 201 11.1.5.3.3 Weaknesses and competitive threats 201 11.1.6 CREO MEDICAL GROUP PLC 202 11.1.6.1 Business overview 202 11.1.6.2 Products offered 203 11.1.6.3 Recent developments 203 11.1.6.3.1 Deals 203 11.1.6.3.2 Expansions 203 11.1.7 HOYA CORPORATION 204 11.1.7.1 Business overview 204 11.1.7.2 Products offered 205 11.1.8 CONMED CORPORATION 207 11.1.8.1 Business overview 207 11.1.8.2 Products offered 208 11.1.9 STERIS 209 11.1.9.1 Business overview 209 11.1.9.2 Products offered 210 11.1.9.3 Recent developments 211 11.1.9.3.1 Deals 211 11.1.10 MTW ENDOSKOPIE MANUFAKTUR 212 11.1.10.1 Business overview 212 11.1.10.2 Products offered 212 11.1.11 OVESCO ENDOSCOPY AG 213 11.1.11.1 Business overview 213 11.1.11.2 Products offered 213 11.1.12 ZEON MEDICAL INC. 214 11.1.12.1 Business overview 214 11.1.12.2 Products offered 214   11.1.13 MICRO-TECH ENDOSCOPY 215 11.1.13.1 Business overview 215 11.1.13.2 Products offered 215 11.1.13.3 Recent developments 216 11.1.13.3.1 Product launches 216 11.1.14 KARL STORZ SE & CO. KG 217 11.1.14.1 Business overview 217 11.1.14.2 Products offered 217 11.1.15 COOK MEDICAL 218 11.1.15.1 Business overview 218 11.1.15.2 Products offered 218 11.1.15.3 Recent developments 219 11.1.15.3.1 Product launches 219 11.2 OTHER COMPANIES 219 11.2.1 LEO MEDICAL CO., LTD. 219 11.2.2 ERBE ELEKTROMEDIZIN GMBH 220 11.2.3 TAEWOONG MEDICAL CO., LTD. 220 11.2.4 DCC HEALTHCARE 221 11.2.5 KOSSEN CO., LTD. 221 11.2.6 INNOVAMEDICA S.P.A. 222 11.2.7 JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD. 223 11.2.8 HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD. 224 11.2.9 BEIJING ZKSK TECHNOLOGY CO., LTD. 224 11.2.10 UPEX-MED CO., LTD. 225 12 APPENDIX 226 12.1 DISCUSSION GUIDE 226 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 231 12.3 CUSTOMIZATION OPTIONS 233 12.4 RELATED REPORTS 233 12.5 AUTHOR DETAILS 234
圖表清單 List of Tables & Figures
TABLE 1 STANDARD CURRENCY CONVERSION RATES 26 TABLE 2 RISK ASSESSMENT: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET 42 TABLE 3 GLOBAL CANCER INCIDENCE FOR GERIATRIC POPULATION (65–85+), 2020 VS. 2040 52 TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57 TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58 TABLE 6 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58 TABLE 7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: ROLE IN ECOSYSTEM 62 TABLE 8 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: PORTER’S FIVE FORCES ANALYSIS 64 TABLE 9 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2024 (USD) 67 TABLE 10 AVERAGE SELLING PRICE TREND OF KNIVES, BY REGION, 2022–2024 (USD) 68 TABLE 11 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: KEY PATENTS, 2023–2025 70 TABLE 12 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: CONFERENCES AND EVENTS, 2025–2026 74 TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS 75 TABLE 14 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 76 TABLE 15 IMPORT DATA FOR HS CODE 901890 BY COUNTRY, 2020–2024 (USD THOUSAND) 78 TABLE 16 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD THOUSAND) 79 TABLE 17 TYPES OF ELECTROSURGICAL KNIVES: FEATURES & USE CASES 80 TABLE 18 KEY COMPANIES IMPLEMENTING AI 86 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 88 TABLE 20 KEY PRODUCT-RELATED TARIFFS FOR ENDOSCOPIC SUBMUCOSAL DISSECTION 88 TABLE 21 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 93 TABLE 22 GASTROSCOPES & COLONOSCOPES: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 94 TABLE 23 KNIVES: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 24 KNIVES: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION, 2023–2030 96 TABLE 25 INJECTION AGENTS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 26 INJECTION AGENTS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION, 2023–2030 98 TABLE 27 TISSUE RETRACTORS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 28 TISSUE RETRACTORS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION, 2023–2030 99 TABLE 29 GRASPERS/CLIPS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 30 GRASPERS/CLIPS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION, 2023–2030 101 TABLE 31 OTHER PRODUCTS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 32 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 104 TABLE 33 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2022 (NUMBER OF PROCEDURES) 104 TABLE 34 ESTIMATED NUMBER OF NEW CASES OF STOMACH CANCER, BY REGION (2022–2040) 105 TABLE 35 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR STOMACH CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 36 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR STOMACH CANCER, BY REGION, 2024 (NUMBER OF PROCEDURES) 106 TABLE 37 ESTIMATED NUMBER OF NEW CASES OF COLON CANCER, BY REGION (2022–2040) 107 TABLE 38 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR COLON CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 39 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR COLON CANCER, BY REGION, 2024 (NUMBER OF PROCEDURES) 108 TABLE 40 ESTIMATED NUMBER OF NEW CASES OF ESOPHAGEAL CANCER, BY REGION (2022–2040) 109 TABLE 41 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR ESOPHAGEAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 42 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR ESOPHAGEAL CANCER, BY REGION, 2024 (NUMBER OF PROCEDURES) 110 TABLE 43 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 112 TABLE 44 HOSPITALS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 45 SPECIALTY CLINICS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 46 AMBULATORY SURGICAL CENTERS: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 47 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 48 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 49 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 50 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 121 TABLE 51 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 122 TABLE 52 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 122 TABLE 53 JAPAN: MACROECONOMIC INDICATORS 123 TABLE 54 JAPAN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 123 TABLE 55 JAPAN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 124 TABLE 56 JAPAN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 124 TABLE 57 CHINA: MACROECONOMIC INDICATORS 125 TABLE 58 CHINA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 125 TABLE 59 CHINA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 125 TABLE 60 CHINA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 126 TABLE 61 INDIA: MACROECONOMIC INDICATORS 127 TABLE 62 INDIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 127 TABLE 63 INDIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 127 TABLE 64 INDIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 128 TABLE 65 SOUTH KOREA: MACROECONOMIC INDICATORS 129 TABLE 66 SOUTH KOREA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 129 TABLE 67 SOUTH KOREA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 129 TABLE 68 SOUTH KOREA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 130 TABLE 69 AUSTRALIA: MACROECONOMIC INDICATORS 130 TABLE 70 AUSTRALIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 131 TABLE 71 AUSTRALIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 131 TABLE 72 AUSTRALIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 131 TABLE 73 REST OF ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 132 TABLE 74 REST OF ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 133 TABLE 75 REST OF ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 133 TABLE 76 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 77 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 135 TABLE 78 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 135 TABLE 79 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 136 TABLE 80 US: MACROECONOMIC INDICATORS 137 TABLE 81 US: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 137 TABLE 82 US: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 137 TABLE 83 US: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 138 TABLE 84 AGE-STANDARDIZED INCIDENCE RATES (ASIR) FOR SELECTED CANCERS IN MEN AND WOMEN IN CANADA, 2020 VS. 2040 139 TABLE 85 CANADA: MACROECONOMIC INDICATORS 140 TABLE 86 CANADA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 140 TABLE 87 CANADA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 140 TABLE 88 CANADA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 141 TABLE 89 EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 90 EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 142 TABLE 91 EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 143 TABLE 92 EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 143 TABLE 93 GERMANY: MACROECONOMIC INDICATORS 144 TABLE 94 GERMANY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 144 TABLE 95 GERMANY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 145 TABLE 96 GERMANY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 145 TABLE 97 FRANCE: MACROECONOMIC INDICATORS 146 TABLE 98 FRANCE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 146 TABLE 99 FRANCE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 147 TABLE 100 FRANCE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 147 TABLE 101 UK: MACROECONOMIC INDICATORS 148 TABLE 102 UK: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 148 TABLE 103 UK: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 149 TABLE 104 UK: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 149 TABLE 105 ITALY: MACROECONOMIC INDICATORS 150 TABLE 106 ITALY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 150 TABLE 107 ITALY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 150 TABLE 108 ITALY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 151 TABLE 109 SPAIN: MACROECONOMIC INDICATORS 151 TABLE 110 SPAIN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 152 TABLE 111 SPAIN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 152 TABLE 112 SPAIN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 152 TABLE 113 REST OF EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 153 TABLE 114 REST OF EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 154 TABLE 115 REST OF EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 154 TABLE 116 LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 117 LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 156 TABLE 118 LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 156 TABLE 119 LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 156 TABLE 120 BRAZIL: MACROECONOMIC INDICATORS 157 TABLE 121 BRAZIL: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 157 TABLE 122 BRAZIL: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 158 TABLE 123 BRAZIL: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 158 TABLE 124 MEXICO: MACROECONOMIC INDICATORS 159 TABLE 125 MEXICO: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 159 TABLE 126 MEXICO: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 159 TABLE 127 MEXICO: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 160 TABLE 128 REST OF LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 161 TABLE 129 REST OF LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 161 TABLE 130 REST OF LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 161 TABLE 131 MIDDLE EAST & AFRICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 163 TABLE 132 MIDDLE EAST & AFRICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 163 TABLE 133 MIDDLE EAST & AFRICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 163 TABLE 134 GCC COUNTRIES: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 165 TABLE 135 GCC COUNTRIES: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2023–2030 (USD MILLION) 165 TABLE 136 GCC COUNTRIES: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2023–2030 (USD MILLION) 165 TABLE 137 KEY DEVELOPMENTS IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, JANUARY 2021–JUNE 2025 167 TABLE 138 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET : DEGREE OF COMPETITION 170 TABLE 139 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET : REGION FOOTPRINT 175 TABLE 140 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: PRODUCT FOOTPRINT 176 TABLE 141 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: INDICATION FOOTPRINT 177 TABLE 142 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: END USER FOOTPRINT 177 TABLE 143 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: KEY STARTUPS/SMES 180 TABLE 144 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY REGION 181 TABLE 145 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET : COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY PRODUCT 181 TABLE 146 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025 184 TABLE 147 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DEALS, JANUARY 2021–JUNE 2025 185 TABLE 148 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: EXPANSIONS, JANUARY 2021–JUNE 2025 186 TABLE 149 OLYMPUS CORPORATION: BUSINESS OVERVIEW 187 TABLE 150 OLYMPUS CORPORATION: PRODUCTS OFFERED 188 TABLE 151 OLYMPUS CORPORATION: DEALS, JANUARY 2021–JUNE 2025 189 TABLE 152 OLYMPUS CORPORATION: EXPANSIONS, JANUARY 2021–JUNE 2025 190 TABLE 153 MEDTRONIC: COMPANY OVERVIEW 191 TABLE 154 MEDTRONIC: PRODUCTS OFFERED 192 TABLE 155 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 194 TABLE 156 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED 195 TABLE 157 FUJIFILM HOLDINGS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 195 TABLE 158 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2021–JUNE 2025 196 TABLE 159 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW 197 TABLE 160 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 198 TABLE 161 SUMITOMO BAKELITE CO., LTD.: BUSINESS OVERVIEW 200 TABLE 162 SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED 201 TABLE 163 CREO MEDICAL GROUP PLC: BUSINESS OVERVIEW 202 TABLE 164 CREO MEDICAL GROUP PLC: PRODUCTS OFFERED 203 TABLE 165 CREO MEDICAL GROUP PLC: DEALS, JANUARY 2021–JUNE 2025 203 TABLE 166 CREO MEDICAL GROUP PLC: EXPANSIONS, JANUARY 2021–JUNE 2025 203 TABLE 167 HOYA CORPORATION: BUSINESS OVERVIEW 204 TABLE 168 HOYA CORPORATION: PRODUCTS OFFERED 205 TABLE 169 CONMED CORPORATION: BUSINESS OVERVIEW 207 TABLE 170 CONMED CORPORATION: PRODUCTS OFFERED 208 TABLE 171 STERIS: COMPANY OVERVIEW 209 TABLE 172 STERIS: PRODUCTS OFFERED 210 TABLE 173 STERIS: DEALS 211 TABLE 174 MTW ENDOSKOPIE MANUFAKTUR: BUSINESS OVERVIEW 212 TABLE 175 MTW ENDOSKOPIE MANUFAKTUR: PRODUCTS OFFERED 212 TABLE 176 OVESCO ENDOSCOPY AG: BUSINESS OVERVIEW 213 TABLE 177 OVESCO ENDOSCOPY AG: PRODUCTS OFFERED 213 TABLE 178 ZEON MEDICAL INC.: BUSINESS OVERVIEW 214 TABLE 179 ZEON MEDICAL INC.: PRODUCTS OFFERED 214 TABLE 180 MICRO-TECH ENDOSCOPY: BUSINESS OVERVIEW 215 TABLE 181 MICRO-TECH ENDOSCOPY: PRODUCTS OFFERED 215 TABLE 182 MICRO-TECH ENDOSCOPY: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025 216 TABLE 183 KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW 217 TABLE 184 KARL STORZ SE & CO. KG.: PRODUCTS OFFERED 217 TABLE 185 COOK MEDICAL: BUSINESS OVERVIEW 218 TABLE 186 COOK MEDICAL: PRODUCTS OFFERED 218 TABLE 187 COOK MEDICAL: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025 219 TABLE 188 LEO MEDICAL CO., LTD.: COMPANY OVERVIEW 219 TABLE 189 ERBE ELEKTROMEDIZIN GMBH: COMPANY OVERVIEW 220 TABLE 190 TAEWOONG MEDICAL CO., LTD.: COMPANY OVERVIEW 220 TABLE 191 DCC HEALTHCARE: COMPANY OVERVIEW 221 TABLE 192 KOSSEN CO., LTD.: COMPANY OVERVIEW 221 TABLE 193 INNOVAMEDICA S.P.A.: COMPANY OVERVIEW 222 TABLE 194 JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 223 TABLE 195 HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD.: COMPANY OVERVIEW 224 TABLE 196 BEIJING ZKSK TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 224 TABLE 197 UPEX-MED CO., LTD.: COMPANY OVERVIEW 225 FIGURE 1 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SEGMENTATION 24 FIGURE 2 RESEARCH DESIGN 28 FIGURE 3 PRIMARY SOURCES 30 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 32 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 33 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 33 FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 34 FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION 35 FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET (2024) 36 FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030) 37 FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38 FIGURE 12 TOP-DOWN APPROACH 38 FIGURE 13 DATA TRIANGULATION METHODOLOGY 40 FIGURE 14 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 43 FIGURE 15 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION) 44 FIGURE 16 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 44 FIGURE 17 GEOGRAPHIC SNAPSHOT OF ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET 45 FIGURE 18 INCREASING USE OF ENDOSCOPY IN DETECTION AND TREATMENT PROCEDURES TO DRIVE MARKET GROWTH 46 FIGURE 19 GASTROSCOPES & COLONOSCOPES HELD LARGEST SHARE OF ASIA PACIFIC MARKET IN 2024 47 FIGURE 20 MARKET IN CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 48 FIGURE 21 ASIA PACIFIC TO BE LARGEST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET 48 FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 49 FIGURE 23 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 FIGURE 24 GLOBAL CANCER INCIDENCE, 2022–2050 51 FIGURE 25 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: ECOSYSTEM ANALYSIS 62 FIGURE 26 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: VALUE CHAIN ANALYSIS 63 FIGURE 27 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: PORTER’S FIVE FORCES ANALYSIS 64 FIGURE 28 AVERAGE SELLING PRICE TREND OF KNIVES, BY REGION, 2022–2024 (USD) 68 FIGURE 29 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: TOP PATENT OWNERS/APPLICANTS AND NUMBER OF PATENTS GRANTED, JANUARY 2015–JUNE 2025 69 FIGURE 30 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: STAKEHOLDERS IN SUPPLY CHAIN 73 FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS 75 FIGURE 32 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 75 FIGURE 33 IMPORT DATA FOR HS CODE 901890 COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 77 FIGURE 34 EXPORT DATA FOR HS CODE 901890 COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 79 FIGURE 35 KEY FEATURES OF GEN AI IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET 86 FIGURE 36 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023 (USD MILLION) 90 FIGURE 37 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION) 90 FIGURE 38 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 91 FIGURE 39 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SNAPSHOT 120 FIGURE 40 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SNAPSHOT 134 FIGURE 41 REVENUE ANALYSIS OF TOP PLAYERS IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, 2020–2024 (USD MILLION) 169 FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 170 FIGURE 43 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 173 FIGURE 44 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: COMPANY FOOTPRINT 174 FIGURE 45 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 179 FIGURE 46 EV/EBITDA OF KEY VENDORS 182 FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 183 FIGURE 48 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: BRAND/PRODUCT COMPARISON 183 FIGURE 49 OLYMPUS CORPORATION: COMPANY SNAPSHOT 188 FIGURE 50 MEDTRONIC: COMPANY SNAPSHOT 192 FIGURE 51 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT 194 FIGURE 52 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 198 FIGURE 53 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT 200 FIGURE 54 CREO MEDICAL GROUP PLC: COMPANY SNAPSHOT 202 FIGURE 55 HOYA CORPORATION: COMPANY SNAPSHOT 205 FIGURE 56 CONMED CORPORATION: COMPANY SNAPSHOT 208 FIGURE 57 STERIS: COMPANY SNAPSHOT 210

同分類最新報告(醫療器材)

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們